Compare NOAH & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | IRWD |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 658.5M |
| IPO Year | 2010 | 2009 |
| Metric | NOAH | IRWD |
|---|---|---|
| Price | $8.45 | $4.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $11.00 | $7.67 |
| AVG Volume (30 Days) | 86.8K | ★ 2.0M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.66% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | $5.71 | $4.39 |
| P/E Ratio | ★ $13.29 | $15.50 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $8.40 | $0.72 |
| 52 Week High | $12.84 | $5.78 |
| Indicator | NOAH | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 25.71 | 53.60 |
| Support Level | N/A | $3.80 |
| Resistance Level | $10.73 | $4.88 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 1.47 | 73.96 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.